11 Educational Resources on Revenue Cycle and Healthcare Compliance 

11 revenue cycle resources for compliance blog header

Revenue leakage from non-compliance with regulations exposes health systems to compliance risks and penalties. We’ve curated eleven resources to help compliance leaders be better prepared to guide alignment between regulatory compliance processes and revenue integrity goals.

Over half of all regulations deal directly with revenue cycle, billing and finance. Most providers still lack an effective system or process to monitor, assess, and validate compliance with those regulations. As a result, these organizations leave themselves open to significant risks, not to mention significant revenue leakage. 

These resources are a great place to start learning more about the revenue angle of healthcare compliance.

Continue reading

OIG Cites Fraud, Waste and Abuse Concerns with Skin Substitutes 

compliance risk for OIG skin sub

Many compliance professionals rely on HHS OIG focus areas as they perform risk assessments and plan subsequent auditing and monitoring activities. In November 2024, the OIG added an item to their Work Plan describing their intention to review Medicare Part B payments for skin substitutes.  

This blog explores the implications for compliance and what health systems need to be aware of.  

Continue reading

Three Strategies to Align Compliance with Revenue Cycle 

align compliance with revenue cycle

The revenue cycle is the process that starts with a patient’s initial appointment and ends with full payment for services. It encompasses all the administrative and clinical functions that contribute to collecting patient service revenue.  For healthcare organizations that provide services to patients, the revenue cycle is the organization’s financial lifeblood. 

Continue reading

What Happens When Integrity and Accountability Fail: Lessons for Compliance Professionals 

“The U.S. opioid epidemic holds important lessons for compliance professionals. This public health crisis is characterized by the widespread misuse of opioid drugs, leading to addiction, overdose deaths and a profound social and economic toll.  

This epidemic has evolved over the past few decades, and while there are many contributing factors, the role of pharmaceutical companies, particularly in the early stages, is widely seen as a critical element.”

Continue reading